Midlands Clinical Ambassador

Robert Mark Temple

Consultant Physician and Nephrologist

Mark is a Consultant Physician and Nephrologist, University Hospitals Birmingham. He pioneered changes to acute medical services in the trust as Clinical Director of acute and general medicine and Associate Medical Director.

As acute care fellow, Royal College of Physicians (RCP), Mark commissioned and edited the acute care toolkit series (2011-14), chaired the hospital pathways work stream of the Future Hospital Commission and was appointed Future Hospital Officer to lead the RCP program implementing the commission’s recommendations. “Delivering the future hospital” was published in November 2017.

Mark is a champion for general internal medicine and a past president and trustee of the West Midlands physicians association. He is a former chair of the medical patient safety executive group (NHSE) and a member of the national patient safety response advisory group (NHSI). In 2017 Mark was associate editor of two issues of the Future Healthcare Journal which focussed on digital healthcare. In 2018 Mark was appointed to the clinical standards committee of NICE and clinical ambassador for the West Midlands for GIRFT.


Five minutes with… Dr Mark Temple

In this short interview, West Midlands clinical ambassador and consultant physician and nephrologist Dr Mark Temple shares his ambitions for GIRFT in the West Midlands and explains what attracted him to the role.

Q. Why did you join the GIRFT programme?

Mark: GIRFT really gets to the heart of delivering high quality clinical services. My role with the Future Hospital Programme at the RCP involved evaluating and improving the delivery of clinical care across a wide range of specialities. I felt GIRFT was an important national program that would build on the work I had done at the RCP.

Q. What is your role within GIRFT?

Mark: Perhaps unusually for the NHS, the role is quite accurately described by its title ‘clinical ambassador’. We act as champions, diplomats, enthusiasts, leaders, influencers and supporters. Ultimately our role is about talking to clinical colleagues and helping them to assess their service and explore different ways of delivering care.

Q. What are you most excited about for the GIRFT programme moving forward?

Mark: As we move into the medical specialties, we need to ensure that GIRFT is as effective as it has proved to be in elective surgery, by really embedding our quality improvement methodology. I’m also keen to ensure that as the programme develops, we have a strong emphasis on patient participation and feedback.

Q. And finally, is there anything else you’d like to share?

Mark: I’m particularly looking forward to starting work on medical workstreams with a high component of unscheduled care in the West Midlands. It’s really important to improve the care of patients who are frail and have cognitive impairment, whose care spans many specialties. Any inpatient care for such patients should be as brief and high quality as their acute illness demands.